New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine.

Slides:

Advertisements

Similar presentations

Results Insulin Treatment of BBDP Rats Results (cont) Optimization of Insulin Treatment for Spontaneous Type 1 Diabetes (T1D) in BBDP/Wor Rats Barak Yahalom,

Advertisements

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes Featured Article: Asa K. Davis, Stephanie N. DuBose, Michael.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Featured Article: Ravi Retnakaran, Caroline K.

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Insulin therapy.

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.

Ali Ardestani, David Rhoads, Ali Tavakkoli

New Insulin Formulations

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes Featured Article: Claudia Cavelti-Weder, M.D., Andrea Babians-Brunner, M.D.,

Toujeo® and it’s Place in Therapy

INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.

Intake of Lactobacillus reuteri Improves Incretin and Insulin Secretion in Glucose Tolerant Humans: A Proof of Concept Featured Article: Marie-Christine.

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

Tresiba- insulin degludec

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Moderate Amounts of Fructose Consumption Impair Insulin Sensitivity in Healthy Young Men: A Randomized Controlled Trial Featured Article: Isabelle Aeberli,

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Increased Circulating Levels of Betatrophin in Newly Diagnosed Type 2 Diabetic Patients Featured Article: Hao Hu, Wenjun Sun, Shuqin Yu, Xiafei Hong, Weiyun.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Trends in Diabetes Incidence: The Framingham Heart Study Featured Article: Tobin M. Abraham, Karol M. Pencina, Michael J. Pencina, and Caroline S. Fox.

Intensive Versus Intermediate Glucose Control in Surgical Intensive Care Unit Patients Featured Article: Takehiro Okabayashi, Yasuo Shima,Tatsuaki Sumiyoshi,

Extra-Virgin Olive Oil Reduces Glycemic Response to a High–Glycemic Index Meal in Patients With Type 1 Diabetes: A Randomized Controlled Trial Featured.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes Featured Article: Jennifer.

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.

Key publication slides

CAN WE IMPROVE POSTPRANDIAL GLUCOSE CONTROL WITH FAST-ACTING INSULINS?

Key publication slides

Mastery of Medicine in Diabetes Management Video Roundtable

Insulin Degludec Drugbank ID :DB09564

Key publication slides

Technosphere® Inhaled Human Insulin has a More Rapid Onset of Action Than Subcutaneous Insulins - Meta Analysis of Clamp data From Three Clinical Studies.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

George Dailey, MD Mayo Clinic Proceedings

Volume 14, Issue 4, Pages (April 2015)

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated albumin (GA; %) and (D) plasma fructosamine (μmol/L) measured.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Figure 3 Pharmacodynamic action profiles of long-acting insulins

Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Glucose, insulin, and AGE levels during an OGC before and after RT

Homeostasis model assessment of insulin resistance (HOMA-IR) scores in obese women and obese women with gestational diabetes mellitus (GDM) at approximately.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

A: The correlation between the GIR and FGU, each measured during the last 40 min of the euglycemic insulin clamp. A: The correlation between the GIR and.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

Intracerebroventricular (ICV) insulin infusion increases TG secretion.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Within-Subject Variability of Insulin Exposure and Metabolic Activity Following Replicate Doses of Technosphere® Insulin Inhalation Powder (TI) in Patients.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.

Distribution of daily frequency of BGM

Spearman rank order correlation between suppression of hepatic glucose production with low insulin infusion and 30-min change in glucose response in women.

Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration.

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients

in Youth With Type 1 Diabetes

A: Glucose levels during basal-bolus and SSI treatment.

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units∙mL2-1 Featured Article: Reinhard H.A. Becker, Raphael Dahmen, Karin Bergmann, Anne Lehmann, Thomas Jax, and Tim Heise Diabetes Care Volume 38: 637-643 April, 2015

STUDY OBJECTIVE To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a new insulin glargine comprising 300 units∙mL–1 (Gla-300), compared with insulin glargine 100 units ∙ mL–1 (Gla-100) at steady state in people with type 1 diabetes Becker R.H.A. et al. Diabetes Care 2015;38:637-643

STUDY DESIGN AND METHODS Randomized, double-blind, crossover study applied the euglycemic clamp technique over 36 h Participants received once-daily subcutaneous administrations of either 0.4 (cohort 1) or 0.6 units∙kg–1 (cohort 2) Gla-300 for 8 days in one treatment period and 0.4 units∙kg–1 Gla-100 for 8 days in the other PK and PD assessments performed on the last treatment day included serum insulin measurements over 36 h Becker R.H.A. et al. Diabetes Care 2015;38:637-643

RESULTS At steady state, insulin concentration and glucose infusion rate proﬁles of Gla-300 were more constant and more evenly distributed over 24 h than those of Gla-100 and lasted longer Tight blood glucose control was maintained for approximately 5 h longer with Gla-300 Becker R.H.A. et al. Diabetes Care 2015;38:637-643

Becker R.H.A. et al. Diabetes Care 2015;38:637-643

Becker R.H.A. et al. Diabetes Care 2015;38:637-643

Becker R.H.A. et al. Diabetes Care 2015;38:637-643

CONCLUSIONS Gla-300 provides more even steady-state PK and PD proﬁles and a longer duration of action than Gla-100 Blood glucose control is extended well beyond 24 h Becker R.H.A. et al. Diabetes Care 2015;38:637-643

Becker R.H.A. et al. Diabetes Care 2015;38:637-643